Although homozygous mutations in EIF2AK4 are more likely to promote HPAH, there is a growing body of research that speculates that the second hit in heterozygous mutations within EIF2AK4 could also potentially lead to PAH. Here, EIF2AK4 is linked to pulmonary arterial hypertension.